UC San Francisco (Video)

Immunotherapy expert Dr. David Oh explains how the immune system can be trained to recognize and fight prostate cancer. He outlines key immune players—dendritic cells and T cells—and describes how immunotherapies target different stages of their interaction with tumors. Oh highlights FDA-approved treatments such as Provenge, a vaccine made from a patient’s own cells, and PD-1 checkpoint inhibitors for patients with specific genetic mutations like microsatellite instability. He also discusses potential autoimmune side effects and emphasizes the importance of genetic testing. Looking ahead, he introduces bispecific T-cell engagers, experimental therapies that physically link T cells to tumors, triggering an immune attack. These promising treatments offer new hope, especially for men with advanced, treatment-resistant prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40811]

As part of the 2025 Developmental Disabilities Conference, Dr. Raul Gutierrez,

Associate Professor of Pediatrics at San Francisco General Hospital, talks about supporting immigrant children. Series: "Developmental Disabilities Update" [Health and Medicine] [Show ID: 40619]

Radiation oncologist Dr. Julian Hong explains how radiation therapy works and its central role in treating prostate cancer, both when the disease is localized and when it has spread to limited areas. He outlines major radiation options, including external beam radiation, stereotactic body radiation therapy (SBRT), and brachytherapy, and describes how treatment plans are carefully tailored using imaging, planning scans, and computer modeling to maximize precision and minimize side effects. Hong highlights advances in targeting and beam modulation, which allow for safer, more effective treatment. He also discusses typical timelines for treatment, short- and long-term side effects, and the importance of ongoing follow-up to manage late effects of therapy. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40803]

Dr. Robert Baron explores current strategies for treating obesity, emphasizing evidence-based approaches to diagnosis, lifestyle change, medication, and long-term weight maintenance. He explains the limitations of body mass index (BMI) as a diagnostic tool and highlights the importance of assessing both excess fat and its health consequences. He reviews dietary principles, including calorie reduction, avoiding added sugars, and the importance of sustainable habits over specific diet types. He also discusses the role of physical activity—particularly strength training—for preserving muscle and improving long-term outcomes. Baron evaluates weight loss medications such as semaglutide and tirzepatide, noting their benefits, side effects, and the need for continued use to maintain weight loss. [Health and Medicine] [Show ID: 40757]

As part of the 2025 Developmental Disabilities Conference, Allen Friedland,

Terri Hancharick and Jack Jadach talk about a collaborative approach to enhancing health in fitness centers. Series: "Developmental Disabilities Update" [Health and Medicine] [Show ID: 40613]

Dr. Robert Baron outlines major updates in type 2 diabetes care, emphasizing that blood sugar control alone does not significantly reduce cardiovascular risk, though it helps prevent microvascular complications. New guidelines now prioritize medications with proven cardiovascular and kidney benefits—GLP-1 receptor agonists and SGLT2 inhibitors—over traditional first-line therapy like metformin. Baron explains how these newer drugs not only lower blood sugar but also reduce the risk of heart attack, stroke, kidney disease, and heart failure, with added benefits such as weight loss. He also covers changes in screening, diagnosis, blood pressure goals, and individualized treatment strategies based on age, comorbidities, and patient preferences. [Health and Medicine] [Show ID: 40756]

Dr. Ivan de Kouchkovsky explains how radioligand therapy delivers targeted radiation to prostate cancer cells using a radioactive isotope attached to a molecule that binds to PSMA, a protein commonly expressed in these tumors. He reviews key clinical trials showing how the therapy improves survival and quality of life for men with metastatic castration-resistant prostate cancer, both after and before chemotherapy. The FDA now approves this approach for patients who have progressed on hormone therapy, even if they haven’t yet received chemotherapy. De Kouchkovsky also highlights efforts to enhance effectiveness by combining therapies, increasing radiation dose, and targeting resistant or PSMA-negative cells. Diagnostic imaging plays a critical role in selecting patients most likely to benefit from treatment. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40810]

UCSF researchers June Chan and Stacey Kenfield share evidence-based strategies for improving prostate cancer outcomes through exercise and diet. They highlight studies showing that physical activity—including resistance and high-intensity interval training—is linked to lower risk of prostate cancer progression and death. They discuss plant-based diets, dietary indices, and specific foods like tomatoes, fish, and nuts, along with the benefits of substituting plant oils for butter. Their analysis includes findings on racial disparities and underscores the need for inclusive research. They also describe current clinical trials exploring lifestyle tools and offer guidance on navigating diet and exercise choices during cancer survivorship. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40808]

Dr. Robert Baron reviews best practices in lipid management for preventing cardiovascular disease, with a focus on statin use. He outlines the strong evidence for statins in reducing heart attack and stroke risk by 25–33%, particularly in patients with clinical atherosclerotic disease, diabetes, or high LDL. He explains why shared decision-making is key in primary prevention, where guidelines vary and risk thresholds are debated. Baron discusses the shift to the newer PREVENT risk calculator, which offers improved accuracy and removes race as a factor. He also explains when additional lipid-lowering medications may be appropriate and clarifies the impact of risk-enhancing factors like family history, coronary artery calcium, and LP(a). [Health and Medicine] [Show ID: 40755]

Dr. Michael Rabow, a palliative care physician, explores the wide-ranging side effects of androgen deprivation therapy (ADT) for prostate cancer and emphasizes strategies to reduce harm while improving quality of life. He outlines cardiovascular, hormonal, and emotional risks—including heart disease, osteoporosis, depression, and loss of vitality—and explains how early assessment and monitoring can help manage these effects. Dr. Rabow highlights evidence-based interventions such as physical activity and cognitive behavioral therapy (CBT), both of which improve symptoms like fatigue, sexual dysfunction, and emotional distress. He also reviews pharmacological options and stresses the importance of personalized, team-based care and shared decision-making over time. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40815]